The synergistic combination of monoclonal anti-CTLA-4 and anti-PD-1 antibodies is also used for the treatment of advanced melanoma, metastatic colorectal cancer that is deficient in highly unstable microsatellite repair, and colon and rectal cancer, as it has been shown to improve the overall patient response rate. The gene discussed is CTLA4; the disease is melanoma.